UCB (OTCMKTS:UCBJY) Shares Gap Up – Should You Buy?

UCB SA (OTCMKTS:UCBJY) gapped up before the market opened on Tuesday. The stock had previously closed at $114.20, but opened at $119.47. UCB shares last traded at $120.66, with a volume of 8,702 shares.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on UCBJY shares. Jefferies Financial Group raised UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. Zacks Research downgraded UCB from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, UCB currently has a consensus rating of “Moderate Buy”.

UCB Trading Up 7.1%

The stock’s fifty day simple moving average is $121.00 and its two-hundred day simple moving average is $135.38.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases in neurology and immunology. The company serves patients and healthcare professionals internationally, with operations and commercial activities spanning Europe, North America and other global markets.

UCB’s neurology portfolio includes medicines such as Vimpat (lacosamide) and Briviact (brivaracetam) for epilepsy, as well as Fintepla (fenfluramine) for certain seizure disorders.